Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT.

MLA

Styczynski, Jan, et al. “Prognostic Impact of EBV Serostatus in Patients with Lymphomas or Chronic Malignancies Undergoing Allogeneic HCT.” Bone Marrow Transplantation, vol. 54, no. 12, Dec. 2019, pp. 2060–71. EBSCOhost, https://doi.org/10.1038/s41409-019-0627-9.

APA

Styczynski, J., Tridello, G., Gil, L., Ljungman, P., Mikulska, M., Ward, K. N., Cordonnier, C., de la Camara, R., Averbuch, D., Knelange, N., Socié, G., Chevallier, P., Blaise, D., Yakoub-Agha, I., Forcade, E., Cornelissen, J., Maertens, J., Petersen, E., Nguyen-Quoc, S., … Cesaro, S. (2019). Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT. Bone Marrow Transplantation, 54(12), 2060–2071. https://doi.org/10.1038/s41409-019-0627-9

Chicago

Styczynski, Jan, Gloria Tridello, Lidia Gil, Per Ljungman, Malgorzata Mikulska, Katherine N Ward, Catherine Cordonnier, et al. 2019. “Prognostic Impact of EBV Serostatus in Patients with Lymphomas or Chronic Malignancies Undergoing Allogeneic HCT.” Bone Marrow Transplantation 54 (12): 2060–71. doi:10.1038/s41409-019-0627-9.